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Abstract 
Sporadic cerebral small vessel disease is considered to be among the most common known 
neuropathological processes and has an important role in stroke, cognitive impairment and 
functional loss in elderly persons. The term is now commonly used to describe a range of 
neuroimaging, neuropathological, and associated clinical features, the pathogenesis of which 
is largely unclear but that are thought to arise from disease affecting the perforating cerebral 
arterioles, capillaries, and venules. Modern neuroimaging has revolutionized our 
understanding of the consequences of small vessels disease on the brain parenchyma, even 
though small arteries, arterioles, capillaries and venules are difficult to directly visualize with 
current techniques used in clinical practise. In this short review we focus on 
histopathological and neuroimaging perspectives, basic definitions and recent advances in the 
field. 
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Introduction 
Most of the modern advances and effective interventions in cerebrovascular disorders target 
disease of large arteries only. Until recently, small cerebral arteries have received little 
attention and clinicians have much less to offer for the prevention and treatment of small 
vessel disease (1). This is partly because small vessels are technically inaccessible to image 
and hard to study directly in vivo; hence the underlying mechanisms of small vessel disease 
remain relatively poorly understood (2). Yet, sporadic small vessel diseases are considered 
to be among the most prevalent known neurologic processes and contribute substantially to 
stroke, cognitive impairment, dementia and other disabilities commonly seen in the elderly 
(including depression, motor and gait disturbances, urinary symptoms and functional 
impairment) (2-4). In addition, small vessel disease can increase mortality (5, 6) and pose 
significant clinical dilemmas in routine practice, including antithrombotic drug use. 
The current review is not intended to provide a comprehensive overview of the all 
manifestations of small vessel disease nor is it intended to review all the aspects related to 
pathology, pathophysiology, and pathogenesis. For background information the reader is 
directed to excellent recent comprehensive reviews on each of these topics (2, 3, 7-9), as 
well as reviews of each of the MRI manifestations of small vessels disease (10-13). Instead, in 
this short review we aim to discuss key neuropathological and neuroimaging definitions, 
focusing on the concept and classification of small vessel disease in the brain, and briefly to 
consider possible future directions for research. Throughout the paper we focus on key 
aspects of the two main types of sporadic small vessel disease, namely cerebral amyloid 
angiopathy and ‘hypertensive arteriopathy’. 
Small vessels in the brain 
The term sporadic cerebral small vessel disease is used with various meanings in different 
contexts, to describe a range of neuroimaging and pathological findings, as well as associated 
clinical and cognitive features or syndromes. However, in its most basic form, the term 
encompasses a group of age-related neuropathological processes affecting the small 
perforating arteries, arterioles, capillaries, and rarely venules in the brain (though venules 
have received little attention in the literature) (1-3). Before considering these pathological 
processes, it is important to define what a small vessel is and specifically, ‘how small a small 
vessel is’. Interestingly, a survey performed among leading neuropathological centres 
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revealed that the definition of a small vessel is not consistent: fewer than 50% of the 
participants agreed on a size limit of less than 500 μm in transverse diameter or all vessels 
located deeper than the cerebral cortex (14). The same survey also reported that the 
laboratory tools used and criteria for small vascular lesions were heterogeneous and could 
significantly influence the obtained results. However, a follow-up survey of the BrainNet 
Europe consortium concluded that a certain level of harmonisation had been reached (15). 
Others have arbitrarily suggested a transverse diameter of ≤300 μm, predominantly 
referring to arterioles – reflecting that pathological processes of the arteriolar tree are 
better characterized than those of other types of small vessel (e.g. capillaries) (2). The 
current definition of small vessels is more inclusive, referring to all vascular structures 
(ranging from around 5 μm to 2 mm in diameter) in the brain parenchyma (i.e. 
intraparenchymal) or the subarachnoid space (i.e. leptomeningeal) and encompassing small 
arteries, arterioles, capillaries, venules and small veins (2). The small arteries and arterioles 
either: (a) penetrate the brain cortex superficially, supplying the grey matter with short 
branches (‘cortical’ arteries) of three lengths (reaching cortical layer III, V and the grey–
white matter junction), and the subcortical white matter with longer branches (‘medullary’ 
arteries) (Fig. 1); or (b) stem from deep arterial perforators at the base of the brain and 
supplying the basal ganglia, thalami and brainstem structures (2, 16). Perforating arterioles 
show a branching pattern that resembles that of poplars rather than oak trees (3, 16, 17). 
Both superficial and deep perforators are end-arterioles and have very limited collateral 
connections with adjacent small vessels until they branch into capillaries. Although capillary 
beds do interconnect to a certain extent, the collateral flow is rather local and limited. This 
has important implications for small infarcts after perforating arteries occlusion (18). Finally, 
the two systems of cerebral perforators do not connect but only meet in a junctional zone 
around the lateral ventricles (16), where leukoaraiosis commonly occurs. Specific small 
vessel pathologies can differentially affect these two systems as well as different ranges of 
vessels within each system (see later). 
The rationale for making a clear distinction between small vessels and large vessels is 
twofold. First, this separation highlights the fact that pathological processes affecting small 
vessels in the brain are to a large extent different from those that affect larger vessels. Small 
and large vessel disease processes can overlap and often co-exist, particularly in the elderly 
(e.g. hypertension-related atherosclerosis and arteriolosclerosis). This is not surprising, as 
the two subtypes of cerebrovascular disease tend to be driven by very similar risk factors, 
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not the least of which is simply aging. However, 'aging,' per se, should not be considered a 
cause of cerebrovascular injury, but rather a variable which probably captures multiple 
accumulating biological changes over time that together affect brain vessels and parenchyma. 
It is also important to keep in mind that large and small vessel systems form a continuum 
and therefore there is a dynamic interaction between large arterial changes and 
microvascular brain injury. For example, progressive age-associated increase in large artery 
stiffness exposes small vessels to higher pulse pressure which can, in turn, lead to 
arteriolosclerosis, progressive white matter damage and cognitive impairment (19). Yet, 
although subdividing cerebrovascular disease into micro-vascular (i.e. small vessel) and 
macro-vascular (i.e. large vessel) components represents an oversimplification, this 
distinction highlights the differences in the putative pathophysiology and clinical and 
pathological consequences of diseases affecting small and large vessels. Approximately one 
third of symptomatic strokes are caused by diseases of small perforating arteries and 
arterioles of the brain; the consequences include lacunar stroke syndromes (20) and most 
cases of spontaneous parenchymal brain haemorrhage (PBH)1 - the most severe and lethal 
type of stroke (1). However, beyond its role in clinically overt acute stroke syndromes, 
small vessel disease causes widespread microvascular damage (seen on neuroimaging or at 
autopsy) which is not symptomatic itself but has important cumulative effects on cognition. 
Cerebral small vessel disease is one of the most important contributors to cognitive 
impairment in the elderly, contributing to up to 45% of dementias (21, 22). The substantial 
cognitive components of microvascular damage in the brain have been often ignored, 
probably overshadowed by the attention given to Alzheimer’s disease, and also due to the 
fact that individual features of small vessel disease have not been traditionally viewed as 
combined components of a group of disorders. As people live longer, the burden of small 
vessel disease is likely to grow, becoming an increasing global healthcare challenge (23). 
Neuroimaging markers of small vessel disease 
Since small vessels (and hence the structural alterations of small vessel disease) cannot be 
visualised easily in vivo with the current neuroimaging techniques used in clinical practice, the 
brain parenchymal magnetic resonance imaging (MRI) lesions which they are thought to 
cause have been adopted as markers of disease involving small vessels (2). As a result, the 
                                            
1 We use this term instead of ‘intracerebral haemorrhage’, as it encompasses cerebellar and brain stem 
haemorrhages as well. 
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term cerebral small vessel disease is frequently used indiscriminately to describe both the 
underlying small vessel pathologies and the neuroimaging correlates of their effects on the 
brain parenchyma (2). The latter are heterogeneous, including both ischaemic and 
haemorrhagic manifestations - now recognised to be inter-related (2, 8, 24). Historically, the 
term small vessel disease has been often (and still is) used misleadingly to describe only the 
ischaemic consequences on imaging (3). However, sporadic small vessel disease is the 
leading cause of PBH, the distribution of which parallels the topography of the underlying 
microvascular pathology, so that spontaneous deep PBH (in the basal ganglia, internal 
capsule and thalami) is predominantly caused by sporadic non-amyloid microangiopathy, 
whereas lobar (cortical-subcortical) PBH is frequently caused by CAA. Lacunes and white 
matter hyperintensities (leukoaraiosis) are well known imaging markers of cerebral small 
vessel disease that have been extensively studied by MRI since the early 1990s (25, 26). 
Advances in neuroimaging now provide an unprecedented ability to investigate more 
complex dynamics (both haemorrhagic and non-haemorrhagic) of small vessel disease in vivo: 
new (or re-discovered) manifestations of small vessel disease visible on conventional 
structural MRI include cerebral microbleeds (27), cortical superficial siderosis (cSS) and 
convexity subarachnoid haemorrhage (7), cerebral microinfarcts at the large end of the size 
spectrum (28) and MRI-visible enlarged perivascular spaces (29) (Fig. 2). Accumulating 
evidence shows that there are also pathological changes associated with small vessel disease 
which are detectable by advanced (e.g., diffusion tensor imaging, magnetisation transfer ratio 
etc.) or high-field MRI. These include tissue changes in white matter areas appearing normal 
on post-mortem MRI (including altered white matter integrity, altered myelination, 
disrupted axonal connections, increased brain water content), secondary focal thinning of 
the cortical grey matter (30) and cortical microinfarcts (Fig. 3) (31). Although ‘invisible’ on 
conventional clinical MRI these small vessel disease-associated changes may contribute 
substantially to abnormalities of clinical function (24). 
Exactly how intrinsic small vessel disease processes result in brain parenchymal injury 
(including the manifestations visible on MRI) and how small vessel disease lesions contribute 
to neurological or cognitive symptoms, are largely unknown. A useful concept to bear in 
mind when approaching neuroimaging markers of small vessel disease (and hence markers of 
pathologic consequences on the brain parenchyma), is that their pathogenic mechanisms are 
probably not uniform, and any given marker may be found in different types of small vessel 
disease (24). For example, in view of different topographical distribution of sporadic non-
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amyloid microangiopathy and CAA, it is hypothesized that cerebral microbleeds have a 
preferential location depending on the underlying small vessel pathology: sporadic non-
amyloid microangiopathy is commonly associated with cerebral microbleeds in deep brain 
regions (e.g. basal ganglia, thalamus and brainstem), whereas CAA is characterised by 
cerebral microbleeds in a lobar distribution (cortical-subcortical).(27) Hence, each marker 
or lesion on neuroimaging has to be interpreted in the context of other information, 
including the specific clinical scenario. 
Neuroimaging standards for research into small vessel disease 
Advances in neuroimaging were recently illustrated in an international working group 
position paper from the Centres of Excellence in Neurodegeneration under the acronym 
STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1) (10). This 
consensus paper presents a unified approach (including common language and minimum 
standards for imaging acquisition and analysis) to small vessel disease as a neuroimaging-
defined concept, which is changing rapidly paralleling the continued advances in 
neuroimaging techniques. Table 1 provides an overview of the six small vessel disease 
lesions included in the STRIVE paper (10). The inclusion of brain atrophy “not related to a 
specific macroscopic focal injury such as trauma or infarction” as another imaging 
manifestation of small vessel disease represents a significant change in thinking in the field 
and highlights the cross-talk between small vessel disease, neurodegeneration and cognitive 
impairment (32, 33). A second advance in the field is the expansion of the spectrum of 
neuroimaging manifestations to include enlarged perivascular spaces; although they have 
been known pathologically for many years, enlarged perivascular spaces visible on MRI have 
received little attention and indeed have been considered normal or unimportant. Only 
recently has evidence begun to emerge that enlarged perivascular spaces are a potential 
neuroimaging marker of small vessel disease. This is particularly interesting in view of the 
growing published work on perivascular fluid drainage impairment and the development of 
cerebral amyloid angiopathy. 
Neuropathological aspects of the two main types of sporadic small 
vessel disease 
Sporadic of small vessel disease is typically – and somewhat arbitrary – categorised in two 
main forms. The first is sporadic CAA, a chronic degenerative disease characterised by 
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progressive deposition of amyloid-β (Aβ) in the media and adventitia of small arteries, 
arterioles and sometimes capillaries in the cerebral cortex, and small arteries, arterioles and 
sometimes venules in the overlying leptomeninges (Fig. 4); the cerebellum may also be 
involved, although usually to a much lesser extent (7, 34-36). The vessels affected by 
amyloid-β can show secondary vasculopathic changes, such as fibrinoid necrosis, loss of 
smooth muscle cells, wall thickening, microaneurysm formation, and perivascular blood 
breakdown products deposition (37). CAA-related vasculopathy is thought to predispose to 
the vascular occlusion or rupture that cause ischaemic or haemorrhagic parenchymal brain 
injury – for a comprehensive summary of the topic, see (8). However, some of the 
ischaemic brain lesions caused by CAA are not currently visible on conventional MRI (e.g. 
microinfarcts, or microstructural alterations) and hence their prevalence and significance in 
CAA have long being underestimated (8). The extent of direct contribution of CAA to 
ischaemic stroke syndromes is currently uncertain, but the presence of multiple lobar 
microbleeds (a marker of the disease) can affect treatment decisions in ischaemic stroke, 
e.g. regarding antithrombotic drug use (38, 39). Similar to the modern concept of cerebral 
small vessel disease, the term CAA now encompasses not only a specific cerebrovascular 
pathological trait and disorder, but also a clinical syndrome and brain parenchymal lesions 
seen on neuroimaging (including a set of diagnostic imaging criteria – the Boston criteria 
(Table 2) (40, 41). 
Some of these ischemic lesions are not visible magnetic resonance imaging (MRI), and their 
prevalence in CAA has therefore long been underestimated.10 
In contrast to CAA which is specific and relatively easy to define, the more common 
form of sporadic small vessel disease is less specific and more difficult to define. The term 
‘hypertensive arteriopathy’ is widely used to describe non-amyloid, degenerative alterations 
in the vessel wall, often related to advanced age (but not clearly age-driven), hypertension, 
diabetes mellitus, cigarette smoking and other common vascular risk factors, and typically 
affecting the small perforating end-arteries of the deep grey nuclei and deep white matter 
(2). It is characterised pathologically by collagenous thickening of the vessel wall with 
narrowing of the lumen and progressive loss of smooth muscle, and sometimes by 
exudation of fibrin and other serum proteins or by scanty mural deposition of lipid (Fig. 5); 
pathological descriptors/subtypes include arteriolosclerosis, fibrinoid necrosis and 
lipohyalinosis. These alterations to the vessel wall are often associated with enlargement of 
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the surrounding perivascular spaces (Fig. 5A-C), and sometimes with microinfarction (Fig. 
5D), thrombosis (Fig. 6A) or microhaemorrhage (Fig. 6B). This very common sporadic form 
of small vessel disease has been variously termed arteriolosclerosis, age-related or vascular 
risk-factor-related small vessel disease, or degenerative microangiopathy in the literature (2, 
42, 43). 
The term ‘hypertensive arteriopathy’ is misleading as it groups together a variety of 
sporadic small vessel disease pathologies not accounted by sporadic CAA but not 
necessarily (or even often) related specifically to hypertension (44), although hypertension 
can influence their evolution. The focus on hypertension perhaps diverts attention from the 
study of other possible factors involved in the initiation and progression of sporadic non-
amyloid small vessel disease. Furthermore, there is not a consensus on the microscopic 
characterisation of small vessel changes of ‘hypertensive arteriopathy’, so that its severity is 
difficult to evaluate in any given case. From a histopathologic perspective, the cerebral 
microvascular changes associated with hypertension are largely identical to those of other 
sporadic non-amyloid, degenerative alterations in the vessel wall (i.e. fibrocollagenous 
thickening and hyalinization, narrowing of the lumen and loss of smooth muscle cells from 
the tunica media). Other possible pathological features can include distal manifestations of 
atherosclerosis (microatheroma, see Fig. 6C) and ‘microaneurysms’ (i.e. elongated and 
tortuous or dilated vessels) (2). Some researchers have subdivided ‘hypertensive 
arteriopathy’ according to the most pronounced structural histopathological abnormalities, 
e.g. distal atherosclerosis, arteriolosclerosis, lipohyalinosis (‘mural disease’), fibrinoid 
necrosis, microaneurysms. (2). These subtypes have a predilection for microvessels of 
slightly different size and distribution and can exist separately or in various combinations 
(Fig. 7). Of these histopathological features, the one most specifically associated with 
hypertension is fibrinoid necrosis, which is more common in hypertensive patients’ brains 
than in those without hypertension (45-47), and is often found in arterioles adjacent to deep 
PBH (46-50). It is worth noting that the more effective treatments for hypertension in 
recent years are likely to have modified the specific pathological features, natural history and 
disease spectrum of hypertensive arteriopathy (44). 
Despite the limitations in definitions and given the lack of an alternative widely accepted 
term, for simplicity and consistency, the term 'hypertensive arteriopathy' is usually adopted 
in recent literature as one of convenience to avoid unnecessarily long and complex terms 
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being repeated. We suggest the alternative umbrella term 'sporadic non-amyloid 
microangiopathy' as being more accurate. Whatever term one prefers for this small vessel 
disease type, the pathological changes associated with sporadic non-amyloid 
microangiopathy presumably impair functional autoregulation (the adjustment of vascular 
calibre to match blood flow to local metabolic demand) and maximal perfusion; the drainage 
of interstitial fluid along the vessel wall and the transport of solutes across it (51); and the 
compliance and tensile strength of the vessels. Not surprisingly, sporadic non-amyloid 
microangiopathy has historically been associated with leukoencephalopathy (52), enlarged 
perivascular spaces (53, 54), lacunar infarcts (55) and intracerebral haemorrhage (56). Table 
3 summarises and compares the most salient pathological and neuroimaging characteristics 
of the two major sporadic small vessel disease processes, which might manifest separately 
or in various combinations. 
Future perspectives 
Although cerebral small vessel disease is emerging as a neuroimaging-defined concept, future 
studies should aim to provide stronger support and further insights on putative MRI 
biomarkers from histopathological-imaging correlations. For example, from the perspective 
of a neuropathologist, evidence from autopsy studies to indicate that signal changes seen on 
imaging and defined as enlarged perivascular spaces actually represent pathological 
expansion of these spaces is still very limited (57, 58). Also, the literature on 
histopathological-neuroimaging correlations of cerebral microbleeds is currently limited to 
fewer than 20 cases (59). More direct correlation studies between neuroimaging 
manifestations of small vessel disease and underlying pathology-morphology are needed if 
these are to be assessed as reliable biomarkers. 
A natural next step is to try to combine these different manifestations of small vessel 
disease on structural imaging, to gauge total brain small vessel disease severity. Recently, the 
approach of assessing total MRI small vessel disease burden into a score has been developed 
and validated in patients at high risk for ischaemic small vessel damage, including lacunar or 
non-disabling cortical stroke (60-62). This comprehensive framework should also be 
evaluated in other types of small vessel disease (60) and in different clinical cohorts, as it has 
potential advantages over individual markers. A total MRI small vessel disease score may 
better stratify the impact of microangiopathy-related damage on clinical outcomes (such as 
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disability and cognition) and ultimately be used as a composite endpoint in clinical trials (63). 
In parallel, studies have suggested neuropathology-based staging schemes to assess the 
spectrum of cerebral small vessel disease (including CAA) in aging brains (64-66), and the 
use of adjunctive biochemical techniques that can be applied to post-mortem brain tissue to 
quantify ante-mortem perfusion, microvessel density, blood-brain barrier function and tissue 
damage (67-71). 
Another key area of need is the identification of neuroimaging biomarker dynamic 
progression over time and determination as to whether this captures clinically relevant 
changes. Further progress in molecular imaging of small vessel disease may allow the direct 
quantification of the vessel pathology in vivo: the detection of vascular amyloid by PET 
scanning with the amyloid radioligand C11-labelled Pittsburgh Compound B (PiB-PET) has 
revolutionised the field (72-74), but no similar methods have yet emerged to measure 
sporadic non-amyloid microangiopathy pathology. Finally, a combined neuroimaging, 
molecular imaging and histopathological approach can provide insights into potential (endo-
)phenotypes of small vessel disease (75), with implications for treatment. Despite recent 
advances in sporadic cerebral small vessel disease processes, many pathophysiological and 
clinical aspects remain unknown, prevention and treatment is still mostly empirical (2) – and 
probably suboptimum or even dangerous (76) – while specific disease-modification is not 
currently available. 
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Box: Search strategy and selection criteria 
References for this Review were identified through searches of PubMed with the search 
terms “small vessel disease(s)”, “white matter lesions”, “white matter changes”, “lacunar 
infarcts”, “cerebral amyloid angioapthy” and “cerebral microbleeds” from 1990 to 2015. 
Articles were also identified through searches of the authors’ own files. The final list of 
references was decided based on their relevance to the themes covered in this review.  
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Tables 
 
Table 1. Neuroimaging manifestations of small vessel disease included in STRIVE v1 and a 
consensus paper on cortical superficial siderosis(12), along with their proposed terms and 
definitions (10). 
 Recent small subcortical infarct: Neuroimaging evidence of recent infarction in the territory of one 
perforating arteriole, with imaging features or clinical symptoms consistent with a lesion occurring in the 
previous few weeks. 
 Lacune of presumed vascular origin: A round or ovoid, subcortical, fluid-filled cavity (signal similar 
to CSF) of between 3 mm and about 15 mm in diameter, consistent with a previous acute small 
subcortical infarct or haemorrhage in the territory of one perforating arteriole. 
 White matter hyperintensity of presumed vascular origin: Signal abnormality of variable size in 
the white matter that shows the following characteristics: hyperintensity on T2-weighted images such as 
fluid-attenuated inversion recovery, without cavitation (signal different from CSF). Lesions in the 
subcortical grey matter or brainstem are not included in this category unless explicitly stated. If deep 
grey matter and brainstem hyperintensities are also included, the collective term should be subcortical 
hyperintensities. 
 Perivascular spaces: Fluid-filled spaces that follow the typical course of a vessel as it goes through grey 
or white matter. The spaces have signal intensity similar to CSF on all sequences. Because they follow the 
course of penetrating vessels, they appear linear when imaged parallel to the course of the vessel, and 
round or ovoid, with a diameter generally smaller than 3 mm, when imaged perpendicular to the course 
of the vessel.  
 Cerebral microbleed: Small (generally 2–5 mm in diameter, but sometimes up to 10 mm) areas of 
signal void with associated blooming seen on T2*-weighted MRI or other sequences that are sensitive to 
susceptibility effects. 
 Brain atrophy: Reduced brain volume that is not related to a specific macroscopic focal injury such as 
trauma or infarction. Thus, infarction is not included in this measure unless explicitly stated. 
------------------------------------------------------------------------------------------------------------------------------ 
 Cortical superficial siderosis (cSS) and acute convexity subarachnoid haemorrhage: Well-
defined, homogeneous hypointense curvilinear signal intensity (black) on T2*-GRE or SWI MRI in the 
superficial layers of the cerebral cortex, within the subarachnoid space, or both. If there is 
corresponding signal hyperintensity in the subarachnoid space on proton density-weighted or FLAIR 
sequences (or hyperdense on CT if available) the term ‘acute cSAH’ is recommended. 
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Table 2. Boston diagnostic criteria for sporadic cerebral amyloid angiopathy. 
(*Modifications compared to the classic Boston criteria based on Linn et al(41)) 
1. Definite CAA 
Full post-mortem examination demonstrating: 
•  Lobar, cortical, or cortical-subcortical haemorrhage 
•  Severe CAA with vasculopathy 
•  Absence of other diagnostic lesion 
2. Probable CAA with supporting pathology 
Clinical data and pathologic tissue (evacuated haematoma or cortical biopsy) demonstrating: 
•  Lobar, cortical, or cortical-subcortical haemorrhage 
•  Some degree of CAA in specimen 
•  Absence of other diagnostic lesion 
3. Probable CAA 
Clinical data and MRI or CT demonstrating: 
• Multiple haemorrhages restricted to lobar, cortical, or cortical-subcortical regions (cerebellar 
haemorrhage allowed) 
 *[OR single lobar, cortical, or cortical-subcortical haemorrhage and focalb or disseminatedc superficial 
siderosis] 
•  Age≥55 years 
•  Absence of other cause of haemorrhagea 
4. Possible CAA 
 Clinical data and MRI or CT demonstrating: 
•  Single lobar, cortical, or cortical-subcortical haemorrhage 
*[OR focalb or disseminatedc superficial siderosis] 
•  Age ≥55 years 
•  Absence of other cause of haemorrhage1 
a Other causes of haemorrhage (differential diagnosis of lobar haemorrhages): antecedent head 
trauma, haemorrhagic transformation of an ischemic stroke, arteriovenous malformation, haemorrhagic 
tumour, warfarin therapy with international normalisation ratio > 3, vasculitis 
b Focal siderosis: siderosis restricted to 3 or fewer sulci. 
c Disseminated siderosis: siderosis affecting at least 4 sulci 
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Table 3. Predominant neuropathological, clinical and neuroimaging characteristics of the 
two major sporadic cerebral small vessel disease subtypes: cerebral amyloid angiopathy and 
‘hypertensive arteriopathy’ 
Characteristics Cerebral amyloid angiopathy 
Sporadic non-amyloid 
microangiopathy 
(‘hypertensive arteriopathy’) 
Small vessel pathology 
Amyloid-β deposition and associated 
vasculopathy in cortical and leptomeningeal 
vessels  
A range of different features, e.g. 
arteriolosclerosis, fibrinoid necrosis, mural 
damage etc. 
Intracerebral haemorrhage Lobar (cortical-subcortical), cerebellar? 
Typically deep: basal ganglia, thalamus, pons 
cerebellum; sometimes lobar 
Ischaemic stroke 
Not typically associated with lacunes 
Uncertain role other than affecting treatment 
decisions, e.g. antithrombotic drugs, 
thrombolysis etc. 
Lacunar syndromes 
Other clinical syndromes 
Transient focal neurological episodes (‘amyloid 
spells’), cognitive impairment and dementia, 
inflammatory CAA 
Vascular cognitive impairment and dementia 
Cerebral microbleeds Lobar Deep 
Cortical superficial siderosis Very common: ~40% in symptomatic CAA Rare: <5% 
MRI-visible perivascular spaces Centrum semiovale (i.e. cerebral white matter) Basal ganglia 
White matter hyperintensities Posterior predominance No predilection for brain region 
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Figures 
 
 
Fig. 1. Schematic representation of penetrating vessel patterns in the cortex. A. Short (S) 
penetrating arterioles (‘cortical’) reaching three different depths in the cortex (i.e. cortical 
layer III, V and the grey–white matter junction, S1-3 respectively), while long penetrators 
(‘medullary’) continue into the subcortical white matter. 
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Fig. 2. Key ischaemic (or non-haemorrhagic) and haemorrhagic imaging features of sporadic 
small vessel disease visible on conventional structural MRI at 1.5T or 3T. (A) Diffusion-
weighted image of an acute small subcortical infarct. (B) A lacune on coronal FLAIR imaging, 
i.e. a CSF-containing cavity, between 3mm to 1.5cm diameter, in deep grey matter. Note the 
marked associated cortical atrophy (including the temporal lobe) in this patient. (C) 
Confluent white matter hyperintensities on FLAIR imaging. (D) MRI-visible perivascular 
spaces in cerebral white matter (i.e. centrum semiovale) on axial T2-weighted imaging, an 
associated neuroimaging feature of cerebral amyloid angiopathy in the appropriate clinical 
context. They are small (generally less than 3mm in diameter) hyperintense lesions 
containing CSF-like fluid, round or linear in shape, depending on their direction and the 
section plane. (E) Multiple strictly lobar microbleeds in a patient with probable cerebral 
amyloid angiopathy. Axial susceptibility-weighted imaging. (F) Axial FLAIR depicting cortical 
brain atrophy not related to specific macroscopic focal injury (e.g. trauma, infarction etc.), 
but only with white matter hyperintensities in an old patient. (G) Cortical superficial 
siderosis on susceptibility-weighted imaging in a patient with a lobar intracerebral 
haemorrhage fulfilling the criteria for probable cerebral amyloid angiopathy. 
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Fig. 3. Cerebral microinfarcts. Top panel: ex vivo images of a brain slice showing a lesion 
with the signal characteristics of a cortical microinfarct on 7T T1 (A) and T2 (B) MRI 
sequences, verified on histopathological examination (right panel, haematoxylin-eosin 
staining and immunostaining for glial fibrillary acidic protein-GFAP). Lower panel: in vivo 
images on 7T FLAIR (C1), 7T T1 (C2), and a 3T T1 (C3) scan showing a probable cortical 
microinfarct, in the same subject. Compared to microinfarcts seen pathologically these MRI-
defined lesions probably are at the large end of the size spectrum. (Images are courtesy of 
Susanne van Veluw and Dr. Geert Jan Biessels on behalf of the Utrecht Vascular Cognitive 
Impairment Study group, Utrecht, the Netherlands) 
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Fig. 4. Microvascular alterations in cerebral amyloid angiopathy (CAA). (A) Concentric 
splitting (arrows) of the walls of arterioles in the leptomeninges. Also note the deeply 
eosinophilic staining of the walls, typical of CAA. (B) A section from the same region of 
temporal lobe immunolabelled for Aβ. Amyloid in the vessel walls is strongly 
immunopositive (brown), as are plaques in the adjacent cortex. The arrow indicates a 
leptomeningeal arteriole with splitting of the vessel wall. (C) Immunohistochemical 
demonstration of Aβ in the walls of several capillaries (arrowheads) in the deep frontal 
cortex. 
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Fig. 5. Pathological findings in 'hypertensive arteriopathy' (sporadic non-amyloid 
microangiopathy). (A) Section through the putamen, showing moderate enlargement of 
perivascular spaces (asterisks) and a deeply eosinophilic fibrinoid exudate within the wall of 
an arteriole (arrow). (B) Perivascular spaces (asterisks) are also enlarged in the subcortical 
white matter, and there is collagenous thickening of the walls of arterioles (arrow). (C) This 
arteriole in the putamen shows a combination of changes: collagenous thickening, exudation 
of fibrinoid material and accumulation of lipid droplets within cells (arrowheads) in the 
vessel wall. (D) Focus of putaminal infarction (arrow) within which are sheets of 
macrophages, a few containing haemosiderin. Lipid-laden macrophages (arrowheads) are 
also present in the wall of an adjacent arteriole, which has a markedly thickened wall and 
narrowed lumen. 
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Fig. 6. Microvascular alterations in 'hypertensive arteriopathy'. (A) Fibrin thrombus within 
an arteriole in the base of the pons. (B) Focal microhaemorrhage, with central accumulation 
of orange-yellow haematoidin and surrounding haemosiderin-laden macrophages. (C) 
Microatheroma within an arteriole in the putamen. 
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Fig. 7. Suggested schematic illustration of the hypothetical relationship between vessel 
diameter, distribution and predilection to different types of pathological process affecting 
cerebral small vessels. The size bar in the upper plot represents a logarithmic scale of the 
vessel diameter range of arteries, arterioles and capillaries.* The schematic representation 
of a perforating arteriole on the top of the scale, again shows a typical branching pattern (3, 
16, 17). Note that 1mm (dotted line in the scale bar) is also the limit of vessels visualization 
in conventional angiography. The range of vessels involved in sporadic cerebral amyloid 
24 
 
angiopathy is indicated by the dark green bar, and the different types and vascular 
involvement in light yellow bars. The range of vessels and the main characteristics of the 
four predominant subtypes under the umbrella term sporadic non-amyloid microangiopathy 
(dark red bar) is shown in light red bars. 
(* As suggested by Brandner S. Histopathology of cerebral microbleeds. In: Werring DJ, ed. Cerebral 
Microbleeds: Pathophysiology to Clinical Practice. Cambridge, England: Cambridge University Press, 2011: 49-
64, Modified and revised with permission) 
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